Meta-analysis shows several MRI-derived parameters were associated with outcomes ...

ONCOMATRYX, a Spanish biopharmaceutical company developing Quantum ADCs against the tumor microenvironment, has successfully raised $67 million to foster the clinical development of novel candidates.

Zongertinib provided substantial clinical benefit for patients with advanced or metastatic HER2-mutant advanced non-small cell lung cancer, surpassing the historical standard of care efficacy for this ...

The trial design for ARASTEP is highlighted in the following schema: Two special considerations for ARASTEP are that all patients have maximally treated pelvic disease and that metastasis directed ...

Metastasis, the spread of cancer from a primary tumor to other parts of the body, is difficult to study in the lab, in part because researchers lack reliable ways to recreate the conditions cancer ...

Metastasis, the spread of cancer from a primary tumor to other parts of the body, is difficult to study in the lab, in part ...

Amini: They play a significant role in how we treat metastatic lung cancer. All patients with stage IV disease should have ...

A recent integrative analysis of single-cell sequencing and single-cell spatial mapping of lymph node metastasis in breast cancer reveals novel mechanisms of the metabolic-immune interaction that ...

Despite a lack of level 1 evidence, metastasis-directed therapy has been increasingly used for the treatment of oligometastatic prostate cancer based on findings from several randomized phase II ...

Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to date Bria-IMT ...

Why do some tumors spread while others remain localized? The mechanisms governing the metastatic potential of tumor cells remain largely unknown—yet understanding this is crucial for optimizing ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...